Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies

被引：148

作者：

Bikker, Jack A. ^{[1
]}

Brooijmans, Natasja ^{[1
]}

Wissner, Allan ^{[1
]}

Mansour, Tarek S. ^{[1
]}

机构：

[1] Wyeth Ayerst Res, Chem Sci, Pearl River, NY 10965 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2009年 / 52卷 / 06期

关键词：

EPIDERMAL-GROWTH-FACTOR; GASTROINTESTINAL STROMAL TUMORS; CELL LUNG-CANCER; FACTOR RECEPTOR KINASE; ABL TYROSINE KINASE; IMATINIB MESYLATE; ACQUIRED-RESISTANCE; EGF RECEPTOR; C-KIT; HYPEREOSINOPHILIC SYNDROME;

D O I：

10.1021/jm8010542

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

[No abstract available]

引用

页码：1493 / 1509

页数：17

共 110 条

[1] Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation [J].

Antonescu, CR ;

Besmer, P ;

Guo, TH ;

Arkun, K ;

Hom, G ;

Koryotowski, B ;

Leversha, MA ;

Jeffrey, PD ;

Desantis, D ;

Singer, S ;

Brennan, MF ;

Maki, RG ;

DeMatteo, RP .

CLINICAL CANCER RESEARCH, 2005, 11 (11) :4182-4190

[2]

Antoniu SA, 2006, CURR OPIN INVEST DR, V7, P980

[3] Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta [J].

Apperley, JF ;

Gardembas, M ;

Melo, JV ;

Russell-Jones, R ;

Bain, BJ ;

Baxter, J ;

Chase, A ;

Chessells, JM ;

Colombat, M ;

Dearden, CE ;

Dimitrijevic, S ;

Mahon, FX ;

Marin, D ;

Nikolova, Z ;

Olavarria, E ;

Silberman, S ;

Schultheis, B ;

Cross, NCP ;

Goldman, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :481-487

[4] Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate [J].

Ault, P ;

Cortes, J ;

Koller, C ;

Kaled, ES ;

Kantarjian, H .

LEUKEMIA RESEARCH, 2002, 26 (09) :881-884

[5] Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL [J].

Azam, M ;

Latek, RR ;

Daley, GQ .

CELL, 2003, 112 (06) :831-843

[6] Activation of tyrosine kinases by mutation of the gatekeeper threonine [J].

Azam, Mohammad ;

Seeliger, Markus A. ;

Gray, Nathanael S. ;

Kuriyan, John ;

Daley, George Q. .

NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2008, 15 (10) :1109-1118

[7] Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance [J].

Azam, Mohammad ;

Nardi, Valentina ;

Shakespeare, William C. ;

Metcalf, Chester A., III ;

Bohacek, Regine S. ;

Wang, Yihan ;

Sundaramoorthi, Raji ;

Sliz, Piotr ;

Veach, Darren R. ;

Bornmann, William G. ;

Clarkson, Bayard ;

Dalgarno, David C. ;

Sawyer, Tomi K. ;

Daley, George Q. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (24) :9244-9249

[8] The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study [J].

Baccarani, Michele ;

Cilloni, Daniela ;

Rondoni, Michela ;

Ottaviani, Emanuela ;

Messa, Francesca ;

Merante, Serena ;

Tiribelli, Mario ;

Buccisano, Francesco ;

Testoni, Nicoletta ;

Gottardi, Enrico ;

de Vivo, Antonio ;

Giugliano, Emilia ;

Iacobucci, Ilaria ;

Paolini, Stefania ;

Soverini, Simona ;

Rosti, Gianantonio ;

Rancati, Francesca ;

Astolfi, Cinzia ;

Pane, Fabrizio ;

Saglio, Giuseppe ;

Martinelli, Giovanni .

HAEMATOLOGICA, 2007, 92 (09) :1173-1179

[9]

BEGHINI A, 1998, BLOOD CELLS, V24

[10] A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy [J].

Bickenbach, Kai ;

Wilcox, Rebecca ;

Veerapong, Jula ;

Kindler, Hedy Lee ;

Posner, Mitchell C. ;

Noffsinger, Amy ;

Roggin, Kevin King .

JOURNAL OF GASTROINTESTINAL SURGERY, 2007, 11 (06) :758-766

← 1 2 3 4 5 6 7 8 9 10 →